ANX Mast Therapeutics, Inc.

SAN DIEGO, Dec. 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and development company focused on commercializing low development risk pharmaceuticals, announced today that Evan M. Levine, chief executive officer, was selected to participate in a panel entitled "New Therapies in Oncology" at the RBC Capital Markets Healthcare Conference at the Westin New York at Times Square in New York, New York on Wednesday, December 13th at 2:30 p.m. Eastern time. Michael Yee, an associate analyst with RBC Capital Markets, will lead the discussion. A live Web cast of the discussion will be available and can be accessed via the "Investors" section of the Company's corporate Web site at http://www.adventrx.com/ under "Events." After the live Web cast, the discussion will remain available on the Company's Web site for 14 days. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing low development risk pharmaceuticals for cancer and infectious disease that enhance the efficacy and/or safety of existing therapies. The Company's lead product candidate, ANX-510 or CoFactor (fotrexorin calcium), currently is in a phase III clinical trial. More information can be found on the Company's corporate web site at http://www.adventrx.com/. Forward-Looking Statement ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual results to differ materially include, but are not limited to: uncertainties inherent in the drug development process; the timing and success of clinical trials; the validity of research results; the receipt of necessary approvals from the FDA and other regulatory agencies; and other risks and uncertainties more fully described in ADVENTRX's press releases and public filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Ioana C. Hone of ADVENTRX Pharmaceuticals, +1-858-552-0866 Web site: http://www.adventrx.com/ Company News On-Call: http://www.prnewswire.com/comp/920134.html

Copyright